Recombinant human platelet-derived growth factor-BB for the treatment of chronic pressure ulcers

M. C. Robson, L. G. Phillips, A. Thomason, B. W. Altrock, P. C. Pence, J. P. Heggers, A. F. Johnston, T. P. McHugh, M. S. Anthony, L. E. Robson, L. L. Odom, D. Yanagihara, G. F. Pierce

Research output: Contribution to journalArticlepeer-review

116 Scopus citations


A randomized phase I/II double-blind, placebo-controlled study was designed to evaluate 1, 10, and 100 μg/ml (0.01, 0.1, and 1.0 μg/cm2) recombinant human BB homodimeric platelet-derived growth factor (rPDGF-BB) applied topically to chronic pressure ulcers for 28 days. Twenty patients were enrolled and completed the trial. No toxicities were associated with rPDGF-BB treatment. Patients treated with 100 μg/ml of rPDGF-BB had a pronounced healing response compared with placebo-treated patients. By day 29, ulcers treated with 100 μg/ml of rPDGF-BB were smaller in remaining size compared with those of placebo-treated patients when the following specific parameters were measured: percentage of initial depth (14.1 ± 7.4 vs. 34.9 ± 6.7) and percentage of initial volume (6.4 ± 4.0 vs. 21.8 ± 5.6). Histological analyses of biopsies revealed active wound healing processes in all groups with no disruption in the normal healing sequence in rPDGF-BB- treated wounds. The results of this small, descriptive study suggest rPDGF-BB is a potent vulnerary agent for accelerating soft-tissue repair, warranting further study.

Original languageEnglish (US)
Pages (from-to)193-201
Number of pages9
JournalAnnals of plastic surgery
Issue number3
StatePublished - 1992

ASJC Scopus subject areas

  • Surgery


Dive into the research topics of 'Recombinant human platelet-derived growth factor-BB for the treatment of chronic pressure ulcers'. Together they form a unique fingerprint.

Cite this